Is there a dominant‐negative effect in individuals with heterozygous disease‐causing variants in COL4A3/COL4A4 ?
Clinical Genetics · 2024-04 · 105 (4) · 406-414
DOI: 10.1111/cge.14471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, online erschienen am 12.01.2024. Verfasst von Korbinian M Riedhammer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, TUM School of Medicine and Health, Munich, Germany. Hauptthemen laut MEDLINE: Collagen Type IV, Nephritis, Hereditary. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, European Society for Paediatric Nephrology.
Abstract (Originalsprache)
Alport syndrome (AS) shows a broad phenotypic spectrum ranging from isolated microscopic hematuria (MH) to end‐stage kidney disease (ESKD). Monoallelic disease‐causing variants in COL4A3 / COL4A4 have been associated with autosomal dominant AS (ADAS) and biallelic variants with autosomal recessive AS (ARAS). The aim of this study was to analyze clinical and genetic data regarding a possible genotype–phenotype correlation in individuals with disease‐causing variants in COL4A3 / COL4A4 . Eighty‐nine individuals carrying at least one COL4A3 / COL4A4 variant classified as (likely) pathogenic according to the American College of Medical Genetics guidelines and current amendments were recruited. Clinical data concerning the prevalence and age of first reported manifestation of MH, proteinuria, ESKD, and extrarenal manifestations were collected. Individuals with monoallelic non‐truncating variants reported a significantly higher prevalence and earlier diagnosis of MH and proteinuria than individuals with monoallelic truncating variants. Individuals with biallelic variants were more severely affected than those with monoallelic variants. Those with biallelic truncating variants were more severely affected than those with compound heterozygous non‐truncating/truncating variants or individuals with biallelic non‐truncating variants. In this study an association of heterozygous non‐truncating COL4A3 / COL4A4 variants with a more severe phenotype in comparison to truncating variants could be shown indicating a potential dominant‐negative effect as an explanation for this observation. The results for individuals with ARAS support the, still scarce, data in the literature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, TUM School of Medicine and Health, Munich, Germany.
- Department of Nephrology, Klinikum rechts der Isar, Technical University of Munich, TUM School of Medicine and Health, Munich, Germany.
- Medical Faculty of Skopje, University Children's Hospital, Macedonia.
- Institute for Mother and Child Health Care of Serbia "Dr Vukan Čupić", Department of Nephrology, University of Belgrade, Faculty of Medicine, Belgrade, Serbia.
- Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians University, Munich, Germany.
- Department of Pediatric Nephrology, Children's Hospital St. Elisabeth and St. Barbara, Halle/Saale, Germany.
ORCID-Profile: Korbinian M Riedhammer, Julia Hoefele
Förderung
- Deutsche Forschungsgemeinschaft
- European Society for Paediatric Nephrology
Zitieren
APA
Riedhammer, K. M., Simmendinger, H., Tasic, V., Putnik, J., Abazi-Emini, N., Stajic, N., Berutti, R., Weidenbusch, M., Patzer, L., Lungu, A., Milosevski-Lomic, G., Günthner, R., Braunisch, M. C., Ćomić, J., & Hoefele, J. (2024). Is there a dominant‐negative effect in individuals with heterozygous disease‐causing variants in COL4A3/COL4A4 ?. Clinical Genetics, 105(4), 406-414. https://doi.org/10.1111/cge.14471
Vancouver
Riedhammer KM, Simmendinger H, Tasic V, Putnik J, Abazi-Emini N, Stajic N, et al. Is there a dominant‐negative effect in individuals with heterozygous disease‐causing variants in COL4A3/COL4A4 ?. Clinical Genetics. 2024;105(4):406-414. doi:10.1111/cge.14471
BibTeX
@article{Riedhammer2024,
author = {Riedhammer, Korbinian M and Simmendinger, Hannes and Tasic, Velibor and Putnik, Jovana and Abazi-Emini, Nora and Stajic, Natasa and Berutti, Riccardo and Weidenbusch, Marc and Patzer, Ludwig and Lungu, Adrian and Milosevski-Lomic, Gordana and Günthner, Roman and Braunisch, Matthias C and Ćomić, Jasmina and Hoefele, Julia},
title = {Is there a dominant‐negative effect in individuals with heterozygous disease‐causing variants in COL4A3/COL4A4 ?},
journal = {Clinical Genetics},
year = {2024},
volume = {105},
number = {4},
pages = {406--414},
doi = {10.1111/cge.14471}
}
EUVIMED